Toku Eyes
San Diego, California, United States
Toku Eyes utilizes multi-modal artificial intelligence and retinal imaging to provide instant healthcare diagnostics and risk assessments. Their platform screens for preventable blindness, cardiovascular disease, and chronic kidney disease risks. Key products include BioAge for biological age determination and MyKidneyAI for diabetes-related kidney risk. Aimed at healthcare professionals, the technology enables early detection and personalized prognostics to improve patient outcomes through accessible, accurate medical analysis. Leveraging a large dataset of retinal images linked to medical records, Toku ensures high-quality standards compliant with ISO 13485, facilitating widespread adoption in clinical settings for better preventive care.
Company Info
- Founded
- 2018
- Website
- tokueyes.com/usa/
Categories
Disease Areas
Technologies
Only accessible to MedStartr community members.
Join nowWhat do you think of Toku Eyes?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.